TY - JOUR
T1 - Targeting Retinoid Receptors to Treat Schizophrenia
T2 - Rationale and Progress to Date
AU - Lerner, Vladimir
AU - McCaffery, Peter J.A.
AU - Ritsner, Michael S.
N1 - Publisher Copyright:
© 2016, Springer International Publishing Switzerland.
PY - 2016/4/1
Y1 - 2016/4/1
N2 - This review provides the rationale and reports on the progress to date regarding the targeting of retinoid receptors for the treatment of schizophrenia and schizoaffective disorder and the role of retinoic acid in functions of the normal brain, and in psychotic states. After a brief introduction, we describe the normal function of retinoic acid in the brain. We then examine the evidence regarding retinoid dysregulation in schizophrenia. Finally, findings from two add-on clinical trials with a retinoid (bexarotene) are discussed. The authors of this review suggest that targeting retinoid receptors may be a novel approach to treat schizophrenia and schizoaffective disorder. Further studies are warranted.
AB - This review provides the rationale and reports on the progress to date regarding the targeting of retinoid receptors for the treatment of schizophrenia and schizoaffective disorder and the role of retinoic acid in functions of the normal brain, and in psychotic states. After a brief introduction, we describe the normal function of retinoic acid in the brain. We then examine the evidence regarding retinoid dysregulation in schizophrenia. Finally, findings from two add-on clinical trials with a retinoid (bexarotene) are discussed. The authors of this review suggest that targeting retinoid receptors may be a novel approach to treat schizophrenia and schizoaffective disorder. Further studies are warranted.
UR - http://www.scopus.com/inward/record.url?scp=84960337267&partnerID=8YFLogxK
U2 - 10.1007/s40263-016-0316-9
DO - 10.1007/s40263-016-0316-9
M3 - Article
AN - SCOPUS:84960337267
SN - 1172-7047
VL - 30
SP - 269
EP - 280
JO - CNS Drugs
JF - CNS Drugs
IS - 4
ER -
